• Users Online: 65
  • Home
  • Print this page
  • Email this page

    Article Cited by others


Fighting tuberculosis by drugs targeting nonreplicating Mycobacterium tuberculosis bacilli

Iacobino Angelo, Piccaro Giovanni, Giannoni Federico, Mustazzolu Alessandro, Fattorini Lanfranco

Year : 2017| Volume: 6| Issue : 3 | Page no: 213-221

   This article has been cited by
1 Drug-Resistant Tuberculosis 2020: Where We Stand
Angelo Iacobino,Lanfranco Fattorini,Federico Giannoni
Applied Sciences. 2020; 10(6): 2153
[Pubmed]  [Google Scholar] [DOI]
2 Molecule Property Analyses of Active Compounds for Mycobacterium Tuberculosis
Vadim Makarov,Elena Salina,Robert C. Reynolds,Phyo Phyo Kyaw Zin,Sean Ekins
Journal of Medicinal Chemistry. 2020;
[Pubmed]  [Google Scholar] [DOI]
3 Advanced Quantification Methods To Improve the 18b Dormancy Model for Assessing the Activity of Tuberculosis Drugs In Vitro
E. D. Pieterman,M. J. Sarink,C. Sala,S. T. Cole,J. E. M. de Steenwinkel,H. I. Bax
Antimicrobial Agents and Chemotherapy. 2020; 64(7)
[Pubmed]  [Google Scholar] [DOI]
4 A rapid, low pH, nutrient stress, assay to determine the bactericidal activity of compounds against non-replicating Mycobacterium tuberculosis
Julie V. Early,Steven Mullen,Tanya Parish,Adelaide Almeida
PLOS ONE. 2019; 14(10): e0222970
[Pubmed]  [Google Scholar] [DOI]
5 Novel MenA Inhibitors Are Bactericidal against Mycobacterium tuberculosis and Synergize with Electron Transport Chain Inhibitors
Bryan J. Berube,Dara Russell,Lina Castro,Seoung-ryoung Choi,Prabagaran Narayanasamy,Tanya Parish
Antimicrobial Agents and Chemotherapy. 2019; 63(6)
[Pubmed]  [Google Scholar] [DOI]
6 Modeling of Mycobacterium tuberculosis dormancy in bacterial cultures
Yana R. Batyrshina,Yakov Sh Schwartz
Tuberculosis. 2019; 117: 7
[Pubmed]  [Google Scholar] [DOI]
7 Pharmacogenetic association between NAT2 gene polymorphisms and isoniazid induced hepatotoxicity: trial sequence meta-analysis as evidence
Saif Khan,Raju K. Mandal,Abdulbaset Mohamed Elasbali,Sajad A. Dar,Arshad Jawed,Mohd Wahid,Harishankar Mahto,Mohtashim Lohani,Bhartendu Nath Mishra,Naseem Akhter,Ali A. Rabaan,Shafiul Haque
Bioscience Reports. 2019; 39(1)
[Pubmed]  [Google Scholar] [DOI]
8 Modeling and Simulation of Pretomanid Pharmacodynamics in Pulmonary Tuberculosis Patients
Michael A. Lyons
Antimicrobial Agents and Chemotherapy. 2019; 63(12)
[Pubmed]  [Google Scholar] [DOI]
9 The Combination Rifampin-Nitazoxanide, but Not Rifampin-Isoniazid-Pyrazinamide-Ethambutol, Kills Dormant Mycobacterium tuberculosis in Hypoxia at Neutral pH
Angelo Iacobino,Federico Giannoni,Manuela Pardini,Giovanni Piccaro,Lanfranco Fattorini
Antimicrobial Agents and Chemotherapy. 2019; 63(7)
[Pubmed]  [Google Scholar] [DOI]
10 Development and biological evaluation of a new nanotheranostic for tuberculosis
Edward Helal-Neto,Suyene Rocha Pinto,Filipe Leal Portilho,Marcellus Dias da Costa,Jonathas Xavier Pereira,Fiammetta Nigro,Eduardo Ricci-Junior,Andre Luis Peixoto Candéa,Maria das Graças Muller de Oliveira Henri,Ralph Santos-Oliveira
Drug Delivery and Translational Research. 2018;
[Pubmed]  [Google Scholar] [DOI]
11 Activity of DNA-targeted C8-linked pyrrolobenzodiazepine–heterocyclic polyamide conjugates against aerobically and hypoxically grown Mycobacterium tuberculosis under acidic and neutral conditions
Angelo Iacobino,Federico Giannoni,Lanfranco Fattorini,Federico Brucoli
The Journal of Antibiotics. 2018;
[Pubmed]  [Google Scholar] [DOI]


Read this article